A Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Patients With Leber's Hereditary Optic Neuropathy

Trial Profile

A Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Patients With Leber's Hereditary Optic Neuropathy

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Idebenone (Primary)
  • Indications Leber's hereditary optic atrophy
  • Focus Registrational; Therapeutic Use
  • Acronyms RHODOS
  • Sponsors Santhera Pharmaceuticals
  • Most Recent Events

    • 12 Jun 2018 According to a Santhera Pharmaceuticals media release, the Korean Ministry of Food and Drug Safety (MFDS) has accepted for review Santhera's new drug application (NDA) for Raxone (idebenone) for the treatment of Leber's hereditary optic neuropathy (LHON). This filing is based on the data package filed in the European MAA.
    • 01 Sep 2015 According to a company media release, Santhera Pharmaceuticals re-filed a Marketing Authorization Application (MAA) and in June 2015, the CHMP recommended granting a marketing authorization for Raxone for the treatment of visual impairment in adolescent and adult patients with LHON.
    • 26 Jun 2015 The EMA's Committee for Medicinal Products for Human Use recommended granting a marketing authorization for idebenone for the treatment of visual impairment in adolescent and adult patients with LHON, according to a Santhera Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top